Alnylam Pharmaceuticals Inc banner

Alnylam Pharmaceuticals Inc
XETRA:DUL

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
XETRA:DUL
Watchlist
Price: 110.36 EUR
Market Cap: €12.8B

Wall St Price Targets

DUL Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast DUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DUL is 395.63 EUR with a low forecast of 207.57 EUR and a high forecast of 517.52 EUR.

Lowest Forecast
Price Target
207.57 EUR
88% Upside
Average Forecast
Price Target
395.63 EUR
258% Upside
Highest Forecast
Price Target
517.52 EUR
369% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
VERK
Verkkokauppa.com Oyj
5% Upside
RLMD
Relmada Therapeutics Inc
111% Upside

Revenue
Forecast

36% / Year
Past Growth
34% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
36% / Year
Past Growth
34% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 3 years is 34%.

Gross Profit
Forecast

N/A
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Gross Profit over the next 3 years is 31%.

Operating Income
Forecast

N/A
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat

The compound annual growth rate for Operating Income over the next 3 years is 72%.

Pre-Tax Income
Forecast

N/A
Past Growth
93% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
93% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.

Net Income
Forecast

N/A
Past Growth
87% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
87% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

The compound annual growth rate for Net Income over the next 3 years is 87%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is DUL's stock price target?
Price Target
395.63 EUR

According to Wall Street analysts, the average 1-year price target for DUL is 395.63 EUR with a low forecast of 207.57 EUR and a high forecast of 517.52 EUR.

What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
34%

Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 3 years is 34%.

What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
31%

The compound annual growth rate for Gross Profit over the next 3 years is 31%.

What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
72%

The compound annual growth rate for Operating Income over the next 3 years is 72%.

What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
93%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.

What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
87%

The compound annual growth rate for Net Income over the next 3 years is 87%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett